Vertex Pharmaceuticals Incorporated (VRTX) Stock

Vertex Pharmaceuticals Incorporated (VRTX) is a Healthcare stock trading at $451.60 (as of 2026-06-18), with a market capitalization of $108.55B and a trailing P/E of 25.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Vertex Pharmaceuticals Incorporated develops and commercializes therapies, including cystic fibrosis treatments such as SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, and TRIKAFTA for patients with specified CFTR mutations. The company also advances additional programs in areas including AAT deficiency, kidney diseases, and diabetes, selling its medicines through specialty channels.

Valuation — source: SEC EDGAR (first-party)
Price$451.60
Market Cap$108.55B
P/E Ratio25.4
EV / EBITDA21.0
Price / Book5.61
Price / Sales8.88
DCF Value (model)$373.16
DCF Upside vs Price-17.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$12.00B
Net Margin32.9%
Return on Equity22.4%
Current Ratio3.02
Revenue Growth (YoY)7.8%
EPS Growth (YoY)61.1%
FCF Growth (YoY)66.4%
Financial Health — source: SEC EDGAR
Altman Z-Score9.79 (safe)
Valuation vs Sector & Industry
Stock P/E25.4
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector21.1%
vs Industry47.1%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderCapital World Investors ($11.33B)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOReshma Kewalramani
Employees6,100
CountryUS
IPO Date1991-07-24

Related Companies (Business model: Big Pharma / Branded Drugs; 8 closest by revenue (market cap unavailable); US-domiciled)

  • Abbott Laboratories (ABT)
  • Amgen Inc. (AMGN)
  • Gilead Sciences, Inc. (GILD)
  • Bristol-Myers Squibb Company (BMY)
  • Regeneron Pharmaceuticals, Inc. (REGN)
  • Biogen Inc. (BIIB)
  • Incyte Corporation (INCY)
  • Zoetis Inc. (ZTS)
VRTX earnings history · VRTX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.